{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:10:11Z","timestamp":1784124611233,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cct.2026.108273","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:39:07Z","timestamp":1772498347000},"page":"108273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol"],"prefix":"10.1016","volume":"164","author":[{"given":"Samuel T.","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Prashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dalthorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Kitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar V.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dziura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Fram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Ostroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cct.2026.108273_bb0005","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2026.108273_bb0010","author":"World Health Organization"},{"issue":"8","key":"10.1016\/j.cct.2026.108273_bb0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr. Serv."},{"issue":"11","key":"10.1016\/j.cct.2026.108273_bb0020","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.cct.2026.108273_bb0025","first-page":"232","article-title":"Identification of a claims data signature and economic consequences for treatment-resistant depression","volume":"63","author":"Greenberg","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.cct.2026.108273_bb0030","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.4088\/JCP.14l09462","article-title":"Clinical characteristics and management of treatment-resistant depression","volume":"76","author":"Conway","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2026.108273_bb0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2008.01.006","article-title":"Serious life events among resistant and non-resistant MDD patients","volume":"110","author":"Amital","year":"2008","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.cct.2026.108273_bb0040","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4088\/JCP.v63n1102","article-title":"The impact of treatment-resistant depression on health care utilization and costs","volume":"63","author":"Crown","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2026.108273_bb0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2026.108273_bb0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.cct.2026.108273_bb0055","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2026.108273_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2026.108273_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2026.108273_bb0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"An update on community ketamine practices","volume":"179","author":"O\u2019Brien","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.cct.2026.108273_bb0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"25","key":"10.1016\/j.cct.2026.108273_bb0080","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cct.2026.108273_bb0085","doi-asserted-by":"crossref","first-page":"pyaf027","DOI":"10.1093\/ijnp\/pyaf027","article-title":"Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study","volume":"28","author":"Zaki","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.cct.2026.108273_bb0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of Esketamine nasal spray: a comprehensive analysis almost 5 years after first approval","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"14","key":"10.1016\/j.cct.2026.108273_bb0095","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.cct.2026.108273_bb0100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","article-title":"Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting","volume":"79","author":"Nikayin","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2026.108273_bb0105","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"S1","key":"10.1016\/j.cct.2026.108273_bb0110","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.2105\/AJPH.2009.166082","article-title":"Socioeconomic disparities in health in the United States: what the patterns tell us","volume":"100","author":"Braveman","year":"2010","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.cct.2026.108273_bb0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-145-1-200607040-00011","article-title":"Good enough: a primer on the analysis and interpretation of noninferiority trials","volume":"145","author":"Kaul","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2026.108273_bb0120","series-title":"A Clinician\u2019s Guide to the Assessment and Interpretation of Noninferiority Trials for Novel Therapies","author":"Oczkowski","year":"2014"},{"issue":"8","key":"10.1016\/j.cct.2026.108273_bb0125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2026.108273_bb0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2026.108273_bb0135","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.cct.2026.108273_bb0140","article-title":"Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study (vol 176, pg 428, <pubYear>2019<\/pubYear>)","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2026.108273_bb0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2026.108273_bb0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.cct.2026.108273_bb0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR* D report","volume":"165","author":"Fava","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.cct.2026.108273_bb0160","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2026.108273_bb0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/da.22875","article-title":"Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression","volume":"36","author":"Salloum","year":"2019","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.cct.2026.108273_bb0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.cct.2026.108273_bb0175","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.cct.2026.108273_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.cct.2026.108273_bb0185","doi-asserted-by":"crossref","first-page":"57118","DOI":"10.4088\/JCP.24m15376","article-title":"Efficacy and safety of ketamine\/Esketamine in bipolar depression in a clinical setting","volume":"85","author":"Santucci","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2026.108273_bb0190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1176\/appi.focus.23021022","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"21","author":"Fancy","year":"2023","journal-title":"FOCUS"},{"issue":"10","key":"10.1016\/j.cct.2026.108273_bb0195","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1176\/appi.ajp.20250276","article-title":"Ketamine for depression, but at what cost? A review of ketamine\u2019s neurotoxic effects from preclinical and human studies","volume":"182","author":"Li","year":"2025","journal-title":"Am. J. Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:34:59Z","timestamp":1779446099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S1551714426000595"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108273","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108273"}}